Reporting from: – 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004 – New England Journal of Medicine In this edition: At the ASCO conference Ga
Reporting from:
– 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004
– New England Journal of Medicine
In this edition:
At the ASCO conference Gary Strauss discussed his results with adjuvant therapy for early non-small cell lung cancer which show improved survival rates. Similarly, results from Timothy Winton’s team point to the addition of chemotherapy, a view endorsed by Bruce Johnson, Aman Buzdar’s group has shown a clear advantage from using chemotherapy including trastuzumab before operating on breast cancer patients. Harold Burstein discussed the liklihood that in patients with HER/2 positive disease trastuzumab-containing neoadjuvant regimens may become standard.
Tim Oliver, described how single-shot carboplatin therapy may be just as effective at removing the risk of further testicular cancer after surgery as radiotherapy, but without collateral iatrogenic cancer risk.
Frances Shepherd, talked about her findings with the targeted agent erlotinib in a phase III trial among patients with advanced non-small cell lung cancer patients who did not respond to standard therapy. Kathy Albain, commented on the clinical implications.
…